A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : FTDP-17 / frontotemporal dementia and parkinsonism linked to chromosome 17

[Related PubMed/MEDLINE]
Total Number of Papers: 247
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   FTDP-17  (>> Co-occurring Abbreviation)
Long Form:   frontotemporal dementia and parkinsonism linked to chromosome 17
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
1  2021 Genetics of frontotemporal dementia in China. ACMG, ALS, FTD, FTLD-TDP, VUS
2  2020 Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect Splicing. snRNP
3  2020 Disease-Associated Mutant Tau Prevents Circadian Changes in the Cytoskeleton of Central Pacemaker Neurons. AD, EB1, hTau
4  2020 Dysregulation of Exosome Cargo by Mutant Tau Expressed in Human-induced Pluripotent Stem Cell (iPSC) Neurons Revealed by Proteomics Analyses. AD, iPSC, mTau, p-Tau
5  2020 Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease. AD, CBD, EOFAD, PSP
6  2019 A Disease-Causing Intronic Point Mutation C19G Alters Tau Exon 10 Splicing via RNA Secondary Structure Rearrangement. ---
7  2019 Amyloid-beta pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo. AD, WT
8  2019 Clinical and Genetic Study of the First Japanese FTDP-17 Patient with a Mutation of +3 in Intron 10 in the MAPT Gene. ---
9  2019 MAPT mutations, tauopathy, and mechanisms of neurodegeneration. AD
10  2019 Reduced expression of dMyc mitigates TauV337M mediated neurotoxicity by preventing the Tau hyperphosphorylation and inducing autophagy in Drosophila. AD, NFTs, PiD
11  2018 Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies. ---
12  2018 Frontotemporal dementia with Parkinsonism linked to chromosome-17 mutations enhance tau oligomer formation. ---
13  2018 FTDP-17 Mutations Alter the Aggregation and Microtubule Stabilization Propensity of Tau in an Isoform-Specific Fashion. ---
14  2018 Longitudinal evaluation of Tau-P301L transgenic mice reveals no cognitive impairments at 17months of age. 5-CSRTT, AD, FTD, OR
15  2018 Sleep Architecture Changed Without RBD in Patients With FTDP-17. PD, PSG
16  2017 11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset. MAPT
17  2017 A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations In Vivo. ---
18  2017 Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. MAPT
19  2017 Increased 4R tau expression and behavioural changes in a novel MAPT-N296H genomic mouse model of tauopathy. PAC
20  2017 Mitochondrial hyperpolarization in iPSC-derived neurons from patients of FTDP-17 with 10+16 MAPT mutation leads to oxidative stress and neurodegeneration. ---
21  2016 Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models. AD, MAPT
22  2016 Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy. GGT, MAPT
23  2016 FTDP-17 with Pick body-like inclusions associated with a novel tau mutation, p.E372G. bvFTD, MAPT
24  2016 Generation of an isogenic, gene-corrected iPSC line from a pre-symptomatic 28-year-old woman with an R406W mutation in the microtubule associated protein tau (MAPT) gene. iPSCs, MAPT
25  2016 Generation of an isogenic, gene-corrected iPSC line from a symptomatic 57-year-old female patient with frontotemporal dementia caused by a P301L mutation in the microtubule associated protein tau (MAPT) gene. iPSCs, MAPT
26  2016 Generation of an isogenic, gene-corrected iPSC line from a symptomatic 59-year-old female patient with frontotemporal dementia caused by an R406W mutation in the microtubule associated protein tau (MAPT) gene. iPSCs, MAPT
27  2016 In Vivo Imaging of Tau Aggregates in the Mouse Retina. ---
28  2016 Induced pluripotent stem cells (iPSCs) derived from a symptomatic carrier of a S305I mutation in the microtubule-associated protein tau (MAPT)-gene causing frontotemporal dementia. iPSCs, MAPT
29  2016 MAPT mutation associated with frontotemporal dementia and parkinsonism (FTDP-17). ---
30  2016 Multiple signaling factors and drugs alleviate neuronal death induced by expression of human and zebrafish tau proteins in vivo. AD
31  2016 Quantitative and combinatory determination of in situ phosphorylation of tau and its FTDP-17 mutants. ---
32  2016 Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation. AD, dMyc
33  2015 Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology. CSF, NFTs
34  2015 Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. iPSCs, NSCs, PPND
35  2015 Homozygous MAPT R406W mutation causing FTDP phenotype: A unique instance of a unique mutation. ---
36  2015 Impaired retrograde transport by the Dynein/Dynactin complex contributes to Tau-induced toxicity. AD
37  2015 Lovastatin suppresses the aberrant tau phosphorylation from FTDP-17 mutation and okadaic acid-induction in rat primary neurons. AD, GSK-3beta, LOV, NMDA, OA, PP2A
38  2015 Structural determinants for alternative splicing regulation of the MAPT pre-mRNA. SRE, WT
39  2015 Systematic review and meta-analysis of Japanese familial Alzheimer's disease and FTDP-17. FAD
40  2014 Bottom-up design of small molecules that stimulate exon 10 skipping in mutant MAPT pre-mRNA. MAPT
41  2014 Cathepsin D in a murine model of frontotemporal dementia with Parkinsonism-linked to chromosome 17. AD
42  2014 Frontotemporal dementia with parkinsonism linked to chromosome 17 with the MAPT R406W mutation presenting with a broad distribution of abundant senile plaques. Abeta42, AD, CERAD, MAPT
43  2014 Huntington's disease is a four-repeat tauopathy with tau nuclear rods. HD
44  2014 Phosphatases of alpha-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism. MAPT, PD
45  2014 Physiological and pathological phosphorylation of tau by Cdk5. AD, CDKs
46  2014 Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia. ---
47  2014 Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer's disease. AD
48  2014 The influence of the DeltaK280 mutation and N- or C-terminal extensions on the structure, dynamics, and fibril morphology of the tau R2 repeat. ---
49  2013 Acetylated tau neuropathology in sporadic and hereditary tauopathies. AD, AGD, FAD, TPSD
50  2013 Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. PTZ
51  2013 Interactions between Abeta and mutated Tau lead to polymorphism and induce aggregation of Abeta-mutated tau oligomeric complexes. ---
52  2013 Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites. ---
53  2013 Lentiviral delivery of the human wild-type tau protein mediates a slow and progressive neurodegenerative tau pathology in the rat brain. LVs, NFD, WT
54  2013 Neurodegenerative disorder FTDP-17-related tau intron 10 +16C → T mutation increases tau exon 10 splicing and causes tauopathy in transgenic mice. ---
55  2013 Ubiquilin 2 is not associated with tau pathology. AD, ALS, PiD
56  2012 A new link to mitochondrial impairment in tauopathies. WT
57  2012 Agraphia in patients with frontotemporal dementia and parkinsonism linked to chromosome 17 with P301L MAPT mutation: dysexecutive, aphasic, apraxic or spatial phenomenon? ---
58  2012 Decrease of the immunophilin FKBP52 accumulation in human brains of Alzheimer's disease and FTDP-17. AD
59  2012 Hrd1 facilitates tau degradation and promotes neuron survival. AD, p-tau
60  2011 Evidence for a Common Founder and Clinical Characteristics of Japanese Families with the MAPT R406W Mutation. SNPs
61  2011 Identification of ligands for the Tau exon 10 splicing regulatory element RNA by using dynamic combinatorial chemistry. CD, DCC
62  2011 Loss of dopaminoreceptive neuron causes L-dopa resistant parkinsonism in tauopathy. DA, DAr
63  2011 NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy. NAD
64  2011 T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice. AD
65  2011 The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner. AD, ANXA2
66  2011 The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies. AD, ER, FTLD-tau, p-IRE1, p-tau, PiD, pPERK, PSP, UPR
67  2011 Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies. AD, FTDP-17T, NFTs, PiD, PSP, TG1, TG2, TGs, TIG3
68  2010 Acetylation of tau inhibits its degradation and contributes to tauopathy. AD, p-tau
69  2010 Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy. ---
70  2010 Disentangling the role of the tau gene locus in sporadic tauopathies. CBD, PD, PSP
71  2010 Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains. AD, MAP
72  2010 Frontotemporal dementia and parkinsonism linked to chromosome 17--the first Polish family. MAPT
73  2010 In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. AChE, HV, PET, PGCs
74  2010 Involvement of puromycin-sensitive aminopeptidase in proteolysis of tau protein in cultured cells, and attenuated proteolysis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) mutant tau. PSA, si
75  2010 SJLB mice develop tauopathy-induced parkinsonism. ---
76  2009 Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. PSP
77  2009 Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing. PTM, SMaRT
78  2009 Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau. ---
79  2009 Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro. AD, PHFs
80  2009 Intrafamilial clinical phenotypic heterogeneity with MAPT gene splice site IVS10+16C>T mutation. MAPT
81  2009 Transgenic Drosophila models of Alzheimer's disease and tauopathies. Abeta42, AD
82  2009 [Clinical, pathological, and genetic characteristics of frontotemporal dementia and parkinsonism linked to chromosome 17 with mutations in the MAPT and PGRN]. MAPT, MAPT, PGRN
83  2009 [Neurodegeneration and inflammation: analysis of a FTDP-17 model mouse]. ACh, AD, DZ, TP
84  2009 [The genetics of dementias. Part 1: Molecular basis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)]. AD, FTD
85  2008 Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. AD
86  2008 In vivo and postmortem clinicoanatomical correlations in frontotemporal dementia and parkinsonism linked to chromosome 17. MAPT, PGRN
87  2008 Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. AD
88  2008 Tau exon 10 alternative splicing and tauopathies. ---
89  2008 Tau-based treatment strategies in neurodegenerative diseases. CBD, PiD, PSP
90  2007 CHIP-ping away at tau. AD, CHIP, p-tau
91  2007 Clinical and genetic features of families with frontotemporal dementia and parkinsonism linked to chromosome 17 with a P301S tau mutation. ---
92  2007 Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). PPND
93  2007 Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. ---
94  2007 Familial early-onset dementia with tau intron 10 + 16 mutation with clinical features similar to those of Alzheimer disease. ---
95  2007 Fibrillogenic nuclei composed of P301L mutant tau induce elongation of P301L tau but not wild-type tau. ---
96  2007 Frontotemporal dementia and Parkinsonism linked to chromosome 17 with the N279K tau mutation. PPND
97  2007 Frontotemporal dementia with tau pathology. ---
98  2007 Frontotemporal lobar degeneration: current concepts in the light of recent advances. ALS, DLDH, FTLD, FTLD-U, TDP-43
99  2007 Hereditary frontotemporal dementia caused by Tau gene mutations. ---
100  2007 Interaction of tau protein with the dynactin complex. ---